Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Carcinoma, Hepatocellular 4Advanced Solid Tumors 3Neoplasms 2Advanced Lung Cancer 2Tislelizumab 1Stomach Neoplasms 1Solid Tumor 1SCLC 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1High-Risk Resectable NSCLC 1Colorectal Neoplasms 1Advanced/Metastatic Solid Malignancies 1Advanced or Metastatic Solid Tumors 1Advanced Solid Tumor 1Advanced Non-Small Cell Lung Cancer 1Adenocarcinoma of Lung 1

Interventions

toripalimab 1tislelizumab 1sintilimab 1pembrolizumab 1durvalumab 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × High-Risk Resectable NSCLC × sintilimab × Clear all
NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1 Completed
27 enrolled
Thoracic

High-Risk Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡